Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) have been assigned an average recommendation of “Moderate Buy” from the six brokerages that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $61.80.

Several research firms recently issued reports on ELVN. Mizuho upped their price target on shares of Enliven Therapeutics from $45.00 to $62.00 and gave the company an “outperform” rating in a report on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Monday, April 20th. Wall Street Zen raised shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, May 11th. Guggenheim started coverage on shares of Enliven Therapeutics in a report on Tuesday, May 12th. They set a “buy” rating and a $80.00 target price on the stock. Finally, The Goldman Sachs Group increased their target price on shares of Enliven Therapeutics from $41.00 to $59.00 and gave the stock a “buy” rating in a report on Friday, May 8th.

Enliven Therapeutics Price Performance

ELVN opened at $34.71 on Monday. The stock has a market capitalization of $2.11 billion, a PE ratio of -20.78 and a beta of 0.29. The firm’s fifty day moving average price is $41.44 and its 200 day moving average price is $30.14. Enliven Therapeutics has a 12-month low of $14.78 and a 12-month high of $48.53.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.06. On average, equities research analysts forecast that Enliven Therapeutics will post -1.57 earnings per share for the current fiscal year.

Institutional Trading of Enliven Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Enliven Therapeutics by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock worth $44,000 after purchasing an additional 594 shares during the period. Invesco Ltd. raised its holdings in shares of Enliven Therapeutics by 4.3% during the second quarter. Invesco Ltd. now owns 21,957 shares of the company’s stock worth $440,000 after purchasing an additional 913 shares during the period. BNP Paribas Financial Markets raised its holdings in shares of Enliven Therapeutics by 33.3% during the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after purchasing an additional 930 shares during the period. KBC Group NV acquired a new stake in shares of Enliven Therapeutics during the first quarter worth $38,000. Finally, Swiss National Bank raised its holdings in shares of Enliven Therapeutics by 1.7% during the fourth quarter. Swiss National Bank now owns 64,273 shares of the company’s stock worth $990,000 after purchasing an additional 1,100 shares during the period. 95.08% of the stock is owned by institutional investors and hedge funds.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.